


**PRELIMINARY AMENDMENT**

DIVISIONAL APPLN OF APPLN NO. 07/700,895


**IN THE CLAIMS:**

Please add claims 52-64 as follows.

~~--52.~~ Prostaglandins E represented by a general formula:



B6 in which X represents:



R<sub>1</sub> represents: a hydrogen atom, a physiologically acceptable saturated residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;

R<sub>2</sub> represents: a hydrogen atom or a methyl group;

R<sub>3</sub> represents: a hydroxyl or hydroxymethyl group;

DIVISIONAL APPLN OF APPLN NO. 07/700,895

R<sub>6</sub> represents: a C<sub>1</sub>-C<sub>9</sub> alkyl group which may have a branch or a double bond, or a C<sub>1</sub>-C<sub>9</sub> alkyl group having an alkoxy substituent group, the C<sub>2</sub>-C<sub>3</sub> bond being a single or double bond.


3  
54. Prostaglandins E as described in claim 1, wherein R<sub>4</sub>  
and/or R<sub>5</sub> is a fluorine atom.

55. Prostaglandins E as described in claim 1, wherein  $R_4$  or  $R_5$  is a methyl group.

56. Prostaglandins E as described in claim 1, which is 13,14-dihydro-15-keto-PGE having one or more fluorine atom(s) on 16-position or alkyl ester thereof.

~~57.~~ Prostaglandins E as described in claim Y, being 13,14-dihydro-6,15-diketo-16R,S-fluoro-PGE, or alkyl ester thereof.


~~58.~~<sup>7</sup> An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E expressed by a general formula:



**PRELIMINARY AMENDMENT**

DIVISIONAL APPLN OF APPLN NO. 07/700,895

in which X represents:



R<sub>1</sub> represents: a hydrogen atom, a physiologically acceptable saturated residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;

R<sub>2</sub> represents: a hydrogen atom or a methyl group;

R<sub>3</sub> represents: a hydroxyl or hydroxymethyl group;

R<sub>4</sub> and R<sub>5</sub> each represents: a hydrogen atom, a methyl group or a halogen atom provided that at least one of R<sub>4</sub> and R<sub>5</sub> is a halogen atom; and

R<sub>6</sub> represents: a C<sub>1</sub>-C<sub>9</sub> alkyl group which may have a branch or a double bond, or a C<sub>1</sub>-C<sub>9</sub> alkyl group having an alkoxy substituent group, the C<sub>2</sub>-C<sub>3</sub> bond being a single or double bond.

59. Prostaglandins E as described in claim 58, wherein R<sub>4</sub> and R<sub>5</sub> are halogen atoms.

60. Prostaglandins E as described in claim 58, wherein R<sub>4</sub> and/or R<sub>5</sub> is a fluorine atom.

61. Prostaglandins E as described in claim 58, wherein R<sub>4</sub> or R<sub>5</sub> is a methyl group.


**PRELIMINARY AMENDMENT**

DIVISIONAL APPLN OF APPLN NO. 07/700,895


62. Prostaglandins E as described in claim 58, being 13,14-dihydro-15-keto-PGE having one or more fluorine atom(s) on 16-position or alkyl ester thereof.

63. Prostaglandins E as described in claim 58, being 13,14-dihydro-~~6,15-diketo-16R,S-fluoro-PGE, or alkyl ester thereof.~~

<sup>13</sup>  
~~64.~~ A treatment of ulcer by administering an anti-ulcer treating effective amount of prostaglandin E to a patient, wherein the prostaglandin E is represented by a formula:



in which X represents:



R<sub>1</sub> represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;